<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557932</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2015-0207</org_study_id>
    <nct_id>NCT02557932</nct_id>
  </id_info>
  <brief_title>Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication</brief_title>
  <official_title>Comparison of 7-day Proton Pump Inhibitor (PPI)-Clarithromycin Containing Triple Therapy and 10-day Bismuth Quadruple Therapy for Helicobacter Eradication as First-line Regimen: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple
      therapy in comparison with that of 7-day PPI-based standard triple as 1st line treatment for
      H. pylori.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current Helicobacter pylori management guidelines recommend proton-pump inhibitor
      (PPI)-Clarithromycin containing triple therapy as 1st line treatment. However, in Korea,
      eradication rates of PPI-Clarithromycin containing triple therapy have been decreased to less
      than 80% due to increased clarithromycin resistance. In areas of high clarithromycin
      resistance (resistance rate more than 15%), guidelines recommend bismuth quadruple therapy as
      a 1st line treatment for H. pylori eradication. Clarithromycin resistance rates reported from
      15.7% to 42.1% in Korea, thus, bismuth quadruple therapy may be better 1st line treatment
      than PPI-Clarithromycin containing triple therapy. However, only one limited study was
      performed to compare effects of the both treatment regimens in Korea. Thus, studies
      evaluating the effect of 10-day bismuth quadruple therapy as the first line treatment for H.
      pylori infection.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>8 weeks after H. pylori treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of H. pylori treatment</measure>
    <time_frame>1 month after H. pylori treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to H. pylori treatment</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H. pylori infection status at 1 year after H. pylori treatment</measure>
    <time_frame>1 year after H. pylori treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H. pylori reinfection rate</measure>
    <time_frame>3 years after success of H. pylori eradication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with H. pylori reinfection</measure>
    <time_frame>3 years after success of H. pylori treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Family History of Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>Standard triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 day-PPI based standard triple therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 day-bismuth quadruple therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard triple therapy</intervention_name>
    <description>Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days</description>
    <arm_group_label>Standard triple therapy</arm_group_label>
    <other_name>7-day PPI-based standard triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth quadruple therapy</intervention_name>
    <description>Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days</description>
    <arm_group_label>Bismuth quadruple therapy</arm_group_label>
    <other_name>10-day Bismuth quadruple therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 or more

          -  Family history of gastric cancer

          -  H. pylori positive by urea breath test

        Exclusion Criteria:

          -  History of H. pylori eradication therapy

          -  History of stomach operation

          -  Other organ cancer within 5 years

          -  Liver cirrhosis or Hepatic insufficiency

          -  Renal insufficiency

          -  Current treatment for serious medical condition which may hinder participation

          -  Contraindication or allergy history for H. pylori treatment regimens

          -  Mental incompetence to understand and sign informed consent

          -  Incompatible conditions to be included into the trial by investigators' decision

          -  Inability to provide an informed consent

          -  History of treatment for peptic ulcer disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Il Ju Choi</investigator_full_name>
    <investigator_title>Department of gastroenterology, Center for Gastric Cancer</investigator_title>
  </responsible_party>
  <keyword>PPI standard triple therapy</keyword>
  <keyword>Bismuth quadruple therapy</keyword>
  <keyword>Helicobacter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

